Author Login IJIRT Partner Network (IPN) Login

A human monoclonal antibody blocking SARS-CoV-2 infection

  • Unique Paper ID: 149461
  • Volume: 6
  • Issue: 12
  • PageNo: 396-401
  • Abstract:
  • The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV). This cross-neutralizing antibody targets a communal epitope on these viruses and offers potential for prevention and treatment of COVID-19.
Download article email to a friend

Cite This Article

  • ISSN: 2349-6002
  • Volume: 6
  • Issue: 12
  • PageNo: 396-401

A human monoclonal antibody blocking SARS-CoV-2 infection

Related Articles

11 Jan, 2022

EVALUATION OF MARKETED EFFERVESCENT TABLETS

Read More
13 Oct, 2021

Bacterial Biofilm Inhibitor

Read More
02 Aug, 2021

The risk of death caused by the use of norepinephrine-resistant hypotension in the condition of septic shock in a patient

Read More
02 Aug, 2021

COMPUTER AIDED DRUG DESIGN (CADD)

Read More
29 Jul, 2021

Impact : Of Second Wave Covid-19 In world

Read More
29 Jul, 2021

The use of milrinone for curing a chronic heart failure

Read More
26 Jul, 2021

Leprosy Disease review

Read More
20 Jul, 2021

Transdermal Drug Delivery System

Read More
13 Jul, 2021

IBUPROFEN: AN OVERVIEW

Read More
13 Jul, 2021

CHEMOTHERAPY FOR BREAST CANCER

Read More
Impact Factor
8.01 (Year 2024)
UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Archive

View More

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry